The CD20 antigen is a transmembrane phosphoprotein that is expressed on the surface of both resting and activated B lymphocytes, but it is lost upon differentiation into plasma cells.
CD20 expression is restricted to B cells and is therefore a useful marker of B-cell lymphomas, as demonstrated in both humans and dogs.
Anti-human CD20 monoclonal antibodies (Rituximab, Ofatumumab, and Obinutuzumab) have been approved by the FDA to treat B-cell non-Hodgkin's lymphoma or chronic lymphocytic leukaemia (CLL).
InvivoGen offers a large choice of anti-human CD20 and anti-dog CD20 monoclonal antibodies, differing in their biological activity.
